BiomX Inc. reported that as of November 25, 2025, the FDA is still reviewing a third-party nebulizer device for their BX004 study for Cystic Fibrosis, but an independent Data Monitoring Committee recommended the study continues with an updated dosing regimen, aiming for topline results in Q2 2026.